

ASX Announcement

Investor webinar – Positive FDA Feedback

Sydney, Australia, 8 December 2025: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company will hold a webinar to update shareholders, investors and other interested parties on the minutes of the US Food and Drug Administration (FDA) meeting held in November. These minutes provide clear alignment across the key elements required to advance azer-cel into a pivotal study and further validate the program's growing clinical and commercial potential.

The webinar will be hosted by CEO & Managing Director, Leslie Chong and Chief Operating Officer, Dr Bradley Glover.

The webinar will be held at 11:00am AEDT on Tuesday 09 December.

Shareholders, investors and interested parties can register to attend the webinar at the link here https://us06web.zoom.us/webinar/register/WN_kj6fL2E6T5qsPmT-J9p4zw

Shareholders are encouraged to submit questions for the webinar in advance via email at: communications@imugene.com

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com



General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

communications@imugene.com

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.